X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (198) 198
gastroenterology & hepatology (175) 175
male (168) 168
female (113) 113
middle aged (103) 103
aged (87) 87
adult (81) 81
animals (72) 72
index medicus (57) 57
rats (46) 46
oncology (45) 45
gastroenterology (41) 41
hepatocellular carcinoma (41) 41
hepatology (39) 39
liver (39) 39
electric communication technique (38) 38
electricity (38) 38
interferon (35) 35
medicine & public health (35) 35
biopsy (34) 34
fibrosis (34) 34
mice (34) 34
japan (33) 33
expression (30) 30
fatty liver (30) 30
hepatitis c (30) 30
liver - pathology (30) 30
transmission of digital information, e.g. telegraphiccommunication (30) 30
hepatitis c virus (29) 29
oxidative stress (29) 29
analysis (27) 27
cirrhosis (26) 26
non-alcoholic fatty liver disease (26) 26
rats, wistar (26) 26
cancer (25) 25
hepatocellular-carcinoma (25) 25
colorectal surgery (24) 24
surgical oncology (24) 24
chronic hepatitis c (23) 23
infection (23) 23
multiplex communication (23) 23
carcinoma, hepatocellular - pathology (22) 22
nonalcoholic steatohepatitis (22) 22
testing (22) 22
insulin resistance (21) 21
investigating or analysing materials by determining theirchemical or physical properties (21) 21
measuring (21) 21
physics (21) 21
aged, 80 and over (20) 20
fatty liver-disease (20) 20
liver neoplasms - pathology (20) 20
retrospective studies (20) 20
alanine transaminase - blood (19) 19
apoptosis (19) 19
immunohistochemistry (19) 19
insulin-resistance (19) 19
liver - metabolism (19) 19
liver diseases (19) 19
natural-history (19) 19
severity of illness index (19) 19
transmission (19) 19
biochemistry & molecular biology (18) 18
genotype (18) 18
risk factors (18) 18
steatohepatitis (18) 18
therapy (18) 18
antiviral agents - therapeutic use (17) 17
gastroenterology and hepatology (17) 17
hepatitis b virus - genetics (17) 17
hepatitis c, chronic - drug therapy (17) 17
liver cirrhosis (17) 17
time factors (17) 17
treatment outcome (17) 17
carcinoma, hepatocellular - genetics (16) 16
care and treatment (16) 16
cells (16) 16
dna (16) 16
ferritin (16) 16
genetic aspects (16) 16
liver cancer (16) 16
mutation (16) 16
ribavirin (16) 16
risk (16) 16
cell biology (15) 15
chronic disease (15) 15
cell line, tumor (14) 14
development and progression (14) 14
hepatitis (14) 14
internal medicine (14) 14
metabolic syndrome (14) 14
prognosis (14) 14
association (13) 13
interferons - therapeutic use (13) 13
liver neoplasms - genetics (13) 13
nafld (13) 13
reverse transcriptase polymerase chain reaction (13) 13
thioredoxin (13) 13
abdominal surgery (12) 12
diagnosis (12) 12
disease (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Gastroenterology, ISSN 0944-1174, 2015, Volume 50, Issue 3, pp. 350 - 360
Journal Article
PLoS ONE, ISSN 1932-6203, 06/2012, Volume 7, Issue 6, p. e38322
Journal Article
Oncology, ISSN 0030-2414, 12/2007, Volume 72, Issue 1, pp. 2 - 15
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer death not only in Japan but worldwide. Clinical Practice Guidelines for HCC were... 
Paper | Consensus-based clinical practice manual | Evidence-based clinical practice guideline | Clinical practice guidelines, manual | Hepatocellular carcinoma, staging, surveillance, diagnostic algorithm, treatment algorithm | diagnostic algorithm | consensus-based clinical practice manual | HEPATIC ARTERIOGRAPHY | ADENOMATOUS HYPERPLASIA | PRACTICE GUIDELINES | JIS SCORE | manual | NATURAL-HISTORY | PROGNOSTIC STAGING SYSTEM | DYSPLASTIC NODULES | treatment algorithm | Clinical practice guidelines | evidence-based clinical practice guideline | ONCOLOGY | CIRRHOTIC LIVERS | surveillance | CLIP SCORE | staging | PATHOLOGICAL CORRELATION | hepatocellular carcinoma | Liver Transplantation | Age Factors | Humans | Middle Aged | Palliative Care | Liver Neoplasms - therapy | Antineoplastic Agents - administration & dosage | Embolization, Therapeutic | Hepatectomy | Societies, Medical | Carcinoma, Hepatocellular - blood supply | Liver Neoplasms - pathology | Liver Neoplasms - virology | Diagnosis, Differential | Carcinoma, Hepatocellular - diagnosis | Japan | Hepatic Artery | Carcinoma, Hepatocellular - virology | Evidence-Based Medicine | Consensus | Algorithms | Liver Neoplasms - diagnosis | Liver Neoplasms - blood supply | Carcinoma, Hepatocellular - pathology | Aged | Carcinoma, Hepatocellular - therapy | Decision Trees | Neoplasm Staging | Population Surveillance | Infusions, Intra-Arterial | Practice Guidelines as Topic | Medical diagnosis | Evidence-based medicine | Liver | Medical treatment | Cancer | Guidelines
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 5/2014, Volume 49, Issue 5, pp. 941 - 953
Efficacy of available therapies for patients with HCV who have previously failed treatment is limited. Two Phase III, open-label trials in Japan investigated... 
Simeprevir | Chronic hepatitis C | Medicine & Public Health | Colorectal Surgery | Treatment-experienced | Hepatology | Gastroenterology | Abdominal Surgery | Surgical Oncology | Sustained virologic response | TMC435 | TELAPREVIR | CHRONIC HEPATITIS-C | SUSTAINED VIROLOGICAL RESPONSE | PROTEASE INHIBITOR | INTERFERON-ALPHA-2B PLUS RIBAVIRIN | PEGYLATED INTERFERON | RESISTANCE | BOCEPREVIR | RETREATMENT | GASTROENTEROLOGY & HEPATOLOGY | EPIDEMIOLOGY | Recombinant Proteins - therapeutic use | Recurrence | Humans | Middle Aged | Hepacivirus - genetics | Polyethylene Glycols - adverse effects | Male | Recombinant Proteins - adverse effects | Polyethylene Glycols - therapeutic use | Young Adult | Ribavirin - administration & dosage | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Drug Administration Schedule | Antiviral Agents - therapeutic use | Japan | Ribavirin - therapeutic use | Interferon-alpha - therapeutic use | Genotype | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Heterocyclic Compounds, 3-Ring - administration & dosage | Heterocyclic Compounds, 3-Ring - adverse effects | Heterocyclic Compounds, 3-Ring - therapeutic use | Sulfonamides - adverse effects | Aged | Interferon-alpha - adverse effects | Sulfonamides - administration & dosage | Medical research | Care and treatment | Medicine, Experimental | Genetic aspects | Interferon | Hepatitis C | Hepatitis C virus
Journal Article
Cancer Letters, ISSN 0304-3835, 2011, Volume 310, Issue 2, pp. 140 - 147
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 1/2011, Volume 46, Issue 1, pp. 101 - 107
Journal Article
Journal Article
Journal Article
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 4/2017, Volume 52, Issue 4, pp. 520 - 533
Elbasvir (EBR) in combination with grazoprevir (GZR) has demonstrated efficacy in patients with hepatitis C virus (HCV) infections in trials primarily... 
Therapy | Medicine & Public Health | Colorectal Surgery | Hepatology | Gastroenterology | Abdominal Surgery | Clinical trial | Genotype | Efficacy | Surgical Oncology | Sustained virologic response | MK-8742 | MK-5172 | OPEN-LABEL | RIBAVIRIN | TRIAL | TREATMENT-NAIVE | HEPATITIS-C VIRUS | CIRRHOSIS | GENOTYPE 1 INFECTION | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY | Quinoxalines - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Benzofurans - administration & dosage | Male | RNA, Viral - blood | Benzofurans - blood | Hepatitis C, Chronic - complications | Quinoxalines - blood | Young Adult | Aged, 80 and over | Adult | Female | Imidazoles - therapeutic use | Drug Therapy, Combination | Quinoxalines - therapeutic use | Hepacivirus - drug effects | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Benzofurans - therapeutic use | Double-Blind Method | Drug Administration Schedule | Quinoxalines - administration & dosage | Administration, Oral | Antiviral Agents - blood | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Benzofurans - adverse effects | Hepatitis C, Chronic - blood | Imidazoles - blood | Liver Cirrhosis - virology | Antiviral Agents - adverse effects | Aged | Sustained Virologic Response | Medicine, Experimental | Clinical trials | Medical research | Hepatitis C virus | Health aspects | Original —Liver, Pancreas, and Biliary Tract
Journal Article
BMC Gastroenterology, ISSN 1471-230X, 01/2012, Volume 12, Issue 1, pp. 2 - 2
Journal Article